CO2021009309A2 - Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo - Google Patents

Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo

Info

Publication number
CO2021009309A2
CO2021009309A2 CONC2021/0009309A CO2021009309A CO2021009309A2 CO 2021009309 A2 CO2021009309 A2 CO 2021009309A2 CO 2021009309 A CO2021009309 A CO 2021009309A CO 2021009309 A2 CO2021009309 A2 CO 2021009309A2
Authority
CO
Colombia
Prior art keywords
crystalline forms
pharmaceutical compositions
salt
organic compound
salts
Prior art date
Application number
CONC2021/0009309A
Other languages
English (en)
Spanish (es)
Inventor
Syed Altaf
Abira Ramakrishnan
Jacob Sizemore
Shijie Zhang
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of CO2021009309A2 publication Critical patent/CO2021009309A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CONC2021/0009309A 2018-12-21 2021-07-15 Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo CO2021009309A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CO2021009309A2 true CO2021009309A2 (es) 2021-10-29

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0009309A CO2021009309A2 (es) 2018-12-21 2021-07-15 Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo

Country Status (22)

Country Link
US (2) US12297179B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898597A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022515239A (cg-RX-API-DMAC7.html)
KR (1) KR20220035022A (cg-RX-API-DMAC7.html)
CN (1) CN113508108B (cg-RX-API-DMAC7.html)
AU (1) AU2019403396B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012305A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001640A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009309A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210394A (cg-RX-API-DMAC7.html)
GE (2) GEP20247683B (cg-RX-API-DMAC7.html)
IL (1) IL284218B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210147A1 (cg-RX-API-DMAC7.html)
MA (1) MA54541A (cg-RX-API-DMAC7.html)
MX (1) MX2021007536A (cg-RX-API-DMAC7.html)
NI (1) NI202100055A (cg-RX-API-DMAC7.html)
PE (2) PE20260309A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551495A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106526UA (cg-RX-API-DMAC7.html)
TW (1) TWI875727B (cg-RX-API-DMAC7.html)
UA (1) UA130491C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020132471A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7622000A (en) * 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
MX2010010300A (es) 2008-03-19 2010-10-26 Osi Pharm Inc Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
US20230285364A1 (en) * 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Also Published As

Publication number Publication date
IL284218A (en) 2021-08-31
AU2019403396B2 (en) 2024-12-12
KR20220035022A (ko) 2022-03-21
NI202100055A (es) 2021-12-01
EP3898597A1 (en) 2021-10-27
JP2026001058A (ja) 2026-01-06
US20250270175A1 (en) 2025-08-28
GEP20247683B (en) 2024-10-28
GEAP202415700A (en) 2024-05-13
PE20212197A1 (es) 2021-11-16
UA130491C2 (uk) 2026-03-04
SG11202106526UA (en) 2021-07-29
JOP20210147A1 (ar) 2023-01-30
JP2022515239A (ja) 2022-02-17
MX2021007536A (es) 2021-09-23
MA54541A (fr) 2022-03-09
PH12021551495A1 (en) 2022-03-07
CA3124401A1 (en) 2020-06-25
JP7749080B2 (ja) 2025-10-03
CN113508108A (zh) 2021-10-15
US20220055995A1 (en) 2022-02-24
BR112021012305A2 (pt) 2021-10-05
CL2021001640A1 (es) 2022-06-03
WO2020132471A1 (en) 2020-06-25
IL284218B2 (en) 2026-05-01
WO2020132471A8 (en) 2020-08-06
US12297179B2 (en) 2025-05-13
CN113508108B (zh) 2024-12-24
PE20260309A1 (es) 2026-02-11
CR20210394A (es) 2021-12-13
TW202039448A (zh) 2020-11-01
IL284218B1 (en) 2026-01-01
JP2024161431A (ja) 2024-11-19
TWI875727B (zh) 2025-03-11
AU2019403396A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
NI202100055A (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéutica del mismo.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CU20200046A7 (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47
MX2020005348A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
MX2021011606A (es) Compuestos dirigidos a prmt5.
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
CR20160287A (es) Inhibidores de syk
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
EA201690094A1 (ru) Ингибиторы syk
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
MX2021004134A (es) Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.
CL2020000376A1 (es) Compuesto pentacíclico.
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2019004266A (es) Compuestos de vinil isoxazolina pesticidas y parasiticidas.
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.